Treatment effects may remain the same even when trial participants differed from the target population

Mike Bradburn(University of Sheffield), Simon Heller(University of Sheffield), Norman Waugh(University of Warwick), David White(University of Sheffield), Peter Mansell(Nottingham University Hospitals NHS Trust), David Hopkins(Kings Health Partners), Ellen Lee(Ford Motor Company (United States)), Daniel Hind(University of Sheffield)
Journal of Clinical Epidemiology
May 11, 2020
10.1016/j.jclinepi.2020.05.001
Cited by 12

Related Papers

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
|Diabetes Care|2019|3.8k
International Consensus on Use of Continuous Glucose Monitoring
|Diabetes Care|2017|2k
Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial
|BMJ|2008|769
Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
|New England Journal of Medicine|2014|624